Protein degrader specialist Lycia prices $318M IPO

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 23 Oct, 01:37 UTC

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.